• Z-IETD-FMK: Caspase-8 Inhibition for Apoptosis and T Cell Re

  2026-07-22

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) is a specific, irreversible caspase-8 inhibitor used to dissect apoptosis and immune cell signaling. It blocks T cell proliferation in response to mitogens, modulates NF-κB activation, and protects procaspases and PARP from cleavage, enabling precise experimental control in apoptosis research.

• V5 Epitope Tag Peptide: A Strategic Catalyst for Translation

  2026-07-22

  This thought-leadership article delves into the mechanistic foundation and translational potential of the V5 Epitope Tag Peptide (GKPIPNPLLGLDST). Blending experimental breakthroughs in single-molecule antibody screening with strategic guidance, we reveal how this tag is redefining protein tagging for Western blot, immunoprecipitation, and dynamic imaging—empowering researchers to bridge discovery and application in molecular biology.

• Targeting FOXM1 to Overcome Chemoresistance in Cancer Cells

  2026-07-21

  A recent study identifies STL427944 as a novel and selective FOXM1 inhibitor, promoting autophagic degradation of FOXM1 to overcome chemoresistance in cancer cells. This mechanism enhances the efficacy of standard chemotherapeutic agents, offering a promising strategy for addressing drug resistance in oncology research.

• Ibrexafungerp (MK 3118): Advanced Antifungal Research Workfl

  2026-07-21

  Ibrexafungerp (MK 3118) offers unique antifungal efficacy against resistant Candida strains, enabling robust in vitro and in vivo workflows. This article delivers actionable protocols, troubleshooting insights, and evidence-based innovation for scientists tackling challenging fungal infections.

• 3X (DYKDDDDK) Peptide: Next-Gen Tagging for Translational Im

  2026-07-20

  Explore the mechanistic and translational advantages of the 3X (DYKDDDDK) Peptide for protein tagging, purification, and structural biology. This article delivers actionable insights for researchers seeking robust, sensitive, and reproducible solutions—drawing from the latest cryo-EM discoveries and workflow innovations.

• Ibrexafungerp (MK 3118): Strategic Insights for Translationa

  2026-07-20

  Explore how Ibrexafungerp (MK 3118), a novel non-competitive 1,3-β-D-glucan synthase inhibitor, is redefining antifungal translational research. This article bridges mechanistic understanding with advanced protocol guidance, highlighting evidence-based strategies for overcoming echinocandin resistance and optimizing preclinical-to-clinical workflows in invasive and vulvovaginal candidiasis models.

• (-)-JQ1: The Gold Standard JQ1 Stereoisomer for BET Controls

  2026-07-19

  (-)-JQ1 sets the benchmark as the definitive inactive JQ1 stereoisomer, enabling rigorous validation in epigenetics and cancer biology studies targeting BET bromodomains. This article details experimental workflows, troubleshooting strategies, and how recent N-MYC/eIF4G1 discoveries in AML research shape best practices for assay design.

• HO-1 and ROS Modulation: Isochlorogenic Acid A Disrupts HBV

  2026-07-18

  The referenced study demonstrates that isochlorogenic acid A impairs hepatitis B virus (HBV) replication by upregulating heme oxygenase-1 (HO-1) and altering intracellular reactive oxygen species (ROS) levels. This dual mechanism disrupts viral morphogenesis, assembly, and cccDNA maintenance, presenting new avenues for antiviral research targeting host redox pathways.

• Cefazedone (Refosporen): Advanced Antibacterial Assay Design

  2026-07-17

  Explore the unique antibacterial properties of Cefazedone (Refosporen), a first-generation cephalosporin, with a focus on optimizing in vitro testing and translational strategies. This article offers a distinct, protocol-driven perspective to empower both research and clinical applications.

• Vasopressin Analogues: Mechanistic Insights and Therapeutic

  2026-07-17

  The reference study systematically reviews vasopressin and its analogues, highlighting the nuanced molecular modifications that underpin their diverse therapeutic properties, such as improved receptor specificity and enhanced metabolic stability. Importantly, it situates lypressin acetate as a natural peptide analog with clinically established and emerging cross-domain applications, informing rational experimental design for translational research.

• PCN Suppresses Hippocampal CYPs via GR to Reduce Phenytoin N

  2026-07-16

  This study reveals that pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 enzymes and attenuates phenytoin-induced neurotoxicity through a glucocorticoid receptor-dependent, PXR-independent mechanism. The findings highlight a novel neuroprotective pathway and suggest new strategies for mitigating adverse CNS effects of antiepileptic drugs.

• Causal Roles of CLEC5A and ISG20 in Atherosclerosis Unveiled

  2026-07-16

  Zhang et al. (2025) integrated Mendelian randomization and eQTL analyses to identify CLEC5A and ISG20 as causally implicated genes in atherosclerosis. Their molecular and experimental findings clarify how ISG20 promotes plaque progression via macrophage-driven lipid accumulation and inflammation, suggesting new avenues for targeted intervention.

• Leucomycin (Kitasamycin): Protocols & Pitfalls in Translatio

  2026-07-15

  Leucomycin (kitasamycin) offers robust, reproducible translational inhibition for antibacterial drug discovery and macrolide resistance research. Explore advanced workflows, comparative advantages, and troubleshooting tips for maximizing its impact in complex bacterial growth inhibition studies.

• Gastrodin and AT1 Blockade Shape Astrocyte Reactivity via RA

  2026-07-15

  This study demonstrates that gastrodin and AT1 receptor inhibition modulate the renin-angiotensin system–SIRT3 axis in astrocytes, with consequences for neuroinflammatory signaling. The findings clarify mechanistic pathways in microglia-astrocyte interactions and highlight the use of selective AT1 antagonists, such as Azilsartan, for dissecting neuroinflammation in vitro.

• PAD4-IN-2 TFA: Protocols and Advances in Tumor-Selective NET

  2026-07-14

  PAD4-IN-2 TFA (Compound 5i TFA) empowers researchers with a tumor-selective approach to inhibiting the PAD4–H3cit–NETs axis, enabling high-precision modulation of tumor immunity and metastasis with minimal toxicity. This article delivers workflow enhancements, troubleshooting guidance, and protocol parameters for leveraging APExBIO’s PAD4-IN-2 TFA in advanced oncology studies.

16173 records 1/1079 page Next 12345 下5页 Last page